⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-28
· read from full text
ⓘ
This editorial highlights the potential impact of combined oral contraceptive pills on thyroid function, noting that estrogen-induced increases in thyroid-binding globulin can alter total and free hormone levels. The authors discuss how these biochemical changes may complicate management for women with existing hypothyroidism and suggest levonorgestrel intrauterine systems as a safer alternative due to their efficacy and favorable side effect profile. While acknowledging the need for further research into long-term thyroid effects, the text positions hormonal contraceptives within a broader context of gynecological management. Relevance to endometriosis: COCPs are cited as a treatment for endometriosis, while LNG-IUS is presented as an alternative therapy for adenomyosis.
Abstract
Dear Editor, Madam, combined oral contraceptive pills (COCPs) remain one of the most widely used contraceptive methods due to their effectiveness and additional therapeutic benefits. Beyond contraception, they aid in regulating menstruation, treating acne, managing endometriosis and dysmenorrhea, and reducing risks of colon, ovarian, and endometrial cancers1. However, their potential risks should not be overlooked. COCPs have been linked to serious side effects such as venous thromboembolism, cerebral thrombosis, myocardial infarction, and pulmonary embolism, as well as an increased risk of breast cancer2. Additionally, they significantly impact the liver and thyroid. The oestrogen component can elevate liver-derived proteins, including thyroid-binding globulin (TBG), leading to altered thyroid hormone levels3. Studies reveal that COCP use correlates with variations in T4 and TSH levels, potentially complicating thyroid function. An increase in TBG leads to elevated total T4 and triiodothyronine (T3) levels, but since more T4 is protein-bound, levels of free (active) T3 and T4 may decrease. These changes could pose challenges for women with existing hypothyroidism as the requirement of levothyroxine would be increased. A study by Qiu et al. reported a higher prevalence of hypothyroidism among women using COCPs4. Given these findings, we urge caution in prescribing COCPs and safer alternatives should be considered—such as the levonorgestrel intrauterine system (LNG-IUS). It has a very good contraceptive efficacy rate5. Over the course of five years of use, most users report less menstrual bleeding in addition to the contraceptive benefits. It has also been used to treat endometrial hyperplasia, adenomyosis, dysmenorrhea, and menorrhagia. Long-term efficacy, excellent user compliance, a swift return to fertility, and a favourable side effect profile make LNG-IUS a compelling alternative to COCPs5. Despite its clinical importance, this subject remains underexplored. We therefore emphasise the need for further research to better understand the long-term effects of COCPs on thyroid function.
Full text
2,470 characters
· extracted from
oa-html
· click to expand
Hormonal birth control and hypothyroidism: time for more research
DOI:
https://doi.org/10.47391/JPMA.30313Keywords:
OCP, HypothyroidismAbstract
Dear Editor,
Madam, combined oral contraceptive pills (COCPs) remain one of the most widely used contraceptive methods due to their effectiveness and additional therapeutic benefits. Beyond contraception, they aid in regulating menstruation, treating acne, managing endometriosis and dysmenorrhea, and reducing risks of colon, ovarian, and endometrial cancers1. However, their potential risks should not be overlooked. COCPs have been linked to serious side effects such as venous thromboembolism, cerebral thrombosis, myocardial infarction, and pulmonary embolism, as well as an increased risk of breast cancer2. Additionally, they significantly impact the liver and thyroid. The oestrogen component can elevate liver-derived proteins, including thyroid-binding globulin (TBG), leading to altered thyroid hormone levels3.
Studies reveal that COCP use correlates with variations in T4 and TSH levels, potentially complicating thyroid function. An increase in TBG leads to elevated total T4 and triiodothyronine (T3) levels, but since more T4 is protein-bound, levels of free (active) T3 and T4 may decrease. These changes could pose challenges for women with existing hypothyroidism as the requirement of levothyroxine would be increased. A study by Qiu et al. reported a higher prevalence of hypothyroidism among women using COCPs4.
Given these findings, we urge caution in prescribing COCPs and safer alternatives should be considered—such as the levonorgestrel intrauterine system (LNG-IUS). It has a very good contraceptive efficacy rate5. Over the course of five years of use, most users report less menstrual bleeding in addition to the contraceptive benefits. It has also been used to treat endometrial hyperplasia, adenomyosis, dysmenorrhea, and menorrhagia. Long-term efficacy, excellent user compliance, a swift return to fertility, and a favourable side effect profile make LNG-IUS a compelling alternative to COCPs5.
Despite its clinical importance, this subject remains underexplored. We therefore emphasise the need for further research to better understand the long-term effects of COCPs on thyroid function.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of the Pakistan Medical Association
This work is licensed under a Creative Commons Attribution 4.0 International License.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.